Fulltext

Economic Evaluation of Human Rotavirus Vaccine in Thailand

Saokaew S 1 , Prasitsuebsai W 2 , Bibera GL 3 , Kengkla K 1 , Zhang XH 3 , Oh KB 2 Show all authors , Lee C 4

Affiliations 

  • 1 Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
  • 2 GSK, Bangkok, Thailand
  • 3 GSK, Singapore, Singapore
  • 4 GSK, Singapore, Singapore. christa.x.lee@gsk.com
Infect Dis Ther, 2019 Sep;8(3):397-415.
PMID: 31197662 DOI: 10.1007/s40121-019-0246-1

Abstract

INTRODUCTION: Rotavirus gastroenteritis is the leading cause of severe diarrhoea among young children < 5 years old. Previous cost-effectiveness analyses on rotavirus (RV) vaccination in Thailand have generated conflicting results. The aim of this current study is to evaluate the economic impact of introducing RV vaccination in Thailand, using updated Thai epidemiological and cost data.

METHODS: Both cost-utility analysis (CUA) and budget impact analysis (BIA) of human rotavirus vaccine (HRV) under a universal mass vaccination (UMV) programme were conducted. A published static, deterministic, cross-sectional population model was adapted to assess costs and health outcomes associated with RV vaccination among Thai children 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications